1. Introduction {#sec1}
===============

Gastric cancer is a common tumor that represents the 3rd global cause of death by cancer. Its annual incidence has significantly decreased, but it remains the fifth cancer in the world \[[@bib1]\]. In Tunisia, while its incidence has also decreased between 1994 and 2009, it\'s still a major health public problem: it represents 5% of all cancers, the first digestive cancer in men and the third in women. At diagnosis tumor is metastatic in half of cases. Histologically, adenocarcinoma (ADK) is the predominant type but we observed an increase in the incidence of PCC subtype in the last years \[[@bib2]\].

The prognostic significance of histological subtype remains unknown. Indeed, while the poor impact of diffuse histological subtype of Lauren\'s classification is now well established \[[@bib3]\], the prognosis of poorly cohesive carcinoma (PCC) is better \[[@bib4], [@bib5]\], equivalent \[[@bib6], [@bib7]\] or worse \[[@bib8], [@bib9]\] than non PCC (NPCC). Furthermore, PCC appears to be resistant to chemotherapy \[[@bib9], [@bib10]\], whereas peri-operative chemotherapy currently represents the therapeutic strategy reference for all gastric adenocarcinoma. In Tunisia, no study on the prognostic significance of histologic subtype was conducted until now.

The aim of our study was to compare the PCC and NPCC prognosis and to determine predictive factors of survival in PCC in a Tunisian cohort.

2. Methods {#sec2}
==========

2.1. Study landscape {#sec2.1}
--------------------

A retrospective comparative monocentric study in the department of pathology of Habib Thameur Hospital during a period of 14 years (2001--2014) was conducted.

2.2. Study design {#sec2.2}
-----------------

\-**Inclusion criteria:** A total of 122 patients with histologically proven gastric ADK, who underwent curative or palliative gastrectomy between 2001 and 2014 at the Habib Thameur hospital in Tunis, Tunisia were included.-**Exclusion criteria:** ADK involving gastro-esophageal junction were excluded from the study.-**Management of patients:** Pre-operative assessment included a complete medical history, physical examination, upper gastro-intestinal endoscopy with biopsies and computed tomographic scans. Gender, age, tumor size, tumor location, gross appearance, venous, perineural, or lymphovascular invasion, histological classification according to world health organization (WHO), TNM stage according to the 8th edition of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) \[[@bib11]\], type of surgery, associated resection and adjuvant chemotherapy were recorded. Linitis was defined macroscopically as partial or complete thickening and rigidity of the gastric wall observed on both pre-operative endoscopy and intra-operative exploration. Pre-operative malnutrition was defined as a weight loss exceeding 10 % of the baseline weight in the last six months.-**Histologic diagnostic criteria:** PCC, as defined by the 2010 WHO classification, includes the signet ring cell carcinoma. It also includes other forms of carcinoma where tumor cell looks like histiocytes, lymphocytes or cells with highly eosinophilic cytoplasm. Some cells may have irregular and bizarre nuclei \[[@bib12]\].-**Statistical analysis:** A comparative analysis between PCC and NPCC was performed. Survival and predictive factors of survival were analyzed. Univariate analysis aimed to determine dependent prognosis factors. Qualitative variables were compared using the chi-square test or Fisher\'s exact test. Quantitative variables were compared by the independent Student-t test. Survival was analyzed by Kaplan--Meier method and included postoperative deaths. The log-rank test was used to compare survival curves. Multivariate analysis aimed to determine independent prognosis factors. It was performed by linear regression by Cox proportional hazards stepwise procedure, including non redundant variables chosen by univariate analysis. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). A p value ≤ 0.05 was considered statistically significant.-**Ethics:** Ethical committee approval of Habib Thameur hospital was obtained (approval number: HTHEC-2018-06). No signed informed consent was obtained by patients due to retrospective collect of data. However, patient\'s confidentiality was respected according to ethical guidelines.

3. Results {#sec3}
==========

3.1. Clinicopathologic findings {#sec3.1}
-------------------------------

Patients\'clinicopathological features are detailed in [Table 1](#tbl1){ref-type="table"}. Of the 122 patients included in the study, 61 (50%) had PCC. Age at initial diagnosis was younger in PCC group (PCC: 57 years; NPCC: 65 years; P = 0.001). Both groups were predominantly of male gender.Table 1Clinicopathological features of patients stratified according to histologic subtype (PCC vs NPCC).Table 1VariableAll patients (n = 122; %)PCC group (n = 61; %)NPCC group (n = 61; %)PGender0.356Male73 (59.8)34 (55.7)39 (63.9)Female49 (40.2)27 (44.3)22 (36.1)Age (years)Mean61.757.57 ± 13.5465.87 ± 12.61**0.001**≤6059 (48.4)39 (63.9)20 (32.8)**0.001**\>6063 (51.6)22 (36.1)41 (67.2)Malnutrition0.781No28 (23)15 (24.6)13 (21.3)Yes89 (73)45 (73.7)44 (72.1)Missed data5 (4)1 (1.7)4 (6.6)Tumor size (cm)Mean6.66.68 ± 3.076.53 ± 3.250.802≤544 (36.1)20 (32.8)26 (42.6)0.291\>568 (55.7)39 (63.9)34 (55.8)Missed data10 (8.2)2 (3.3)1 (1.6)Macroscopic type0.111Ulcerated or depressed38 (31.1)24 (39.3)14 (22.9)Protruded78 (64)33 (54.1)45 (73.8)Flat or slightly elevated5 (4.1)3 (5)2 (3.3)Missed data1 (0.8)1 (1.6)0Linitis17 (13.9)15 (24.6)2 (3.3)**0.001**Tumor location0.683Body60 (49.2)30 (49.2)30 (49.2)Antrum58 (47.5)28 (45.9)30 (49.2)Whole stomach4 (3.3)3 (4.9)1 (1.6)Involvement of adjacent organs24 (19.7)11 (18)13 (21.3)0.580Gastrectomy0.440 Total82 (67.2)43 (70.5)39 (63.9) Subtotal40 (32.8)18 (29.5)22 (36.1)Number of lymph nodes retrieved0.220 ≤1633 (27)14 (23)19 (31.1) \<16-25≤40 (32.8)24 (39.3)16 (26.2) \>2549 (40.2)23 (37.7)26 (42.6)Postoperative complication24 (19.7)12 (19.7)12 (19.7)0.920Postoperative chemotherapy40 (32.7)21 (34.4)19 (31.1)0.579Lymphovascular invasion99 (81.1)49 (80.3)50 (82)0.783Perineural invasion90 (73.8)53 (86.9)37 (60.7)**0.001**Stroma**\<0.001**Desmoplasia37 (32.2)29 (48.3)8 (14.5) Inflammatory microenvironment78 (67.8)31 (51.7)47 (85.5)Epithelial abnormality**\<0.001** Metaplasia66 (57,9)22 (36.1)44 (72.1) Dysplasia16 (14)2 (3.3)14 (23)Resection**0.004**complete (R0)97 (79.5)42 (68.9)55 (90.2)incomplete (R1-R2)25 (20.5)19 (31.1)6 (9.8)pT stage**0.033** T111 (9)2 (3.3)9 (14.8) T27 (5.7)4 (6.6)3 (4.9) T349 (40.2)21 (34.4)28 (45.9) T455 (45.1)34 (55.7)21 (34.4)pN stage**\<0.001** N030 (24.6)14 (23)16 (26.2) N120 (16.4)3 (4.9)17 (27.9) N214 (11.5)4 (6.6)10 (16.4) N358 (47.5)40 (65.6)18 (29.5)pM stage0.185 M096 (78.7)45 (73.8)51 (83.6) M126 (21.3)16 (26.2)10 (16.4)pTNM stage**\<0.001** Stage I13 (10.7)5 (8.2)8 (13.1) Stage II30 (24.6)11 (18)19 (31.1) Stage III53 (43.3)29 (47.5)24 (39.3) Stage IV26 (21.3)16 (26.2)10 (16.4)Peritoneal carcinomatosis17 (13.9)14 (23)3 (4.9)**0.004**Hepatic metastasis8 (6.5)1 (1.6)7 (11.5)**0.031**Recurrence33 (27)18 (27.7)15 (23.1)0.348 Peritoneal23 (18.5)14 (77.7)9 (60)0.234 Loco-regional9 (7.3)5 (27.7)4 (26.6)0.627 Distant21 (17.2)11 (61.1)10 (66.6)0.741[^1][^2]

Intestinal metaplasia and dysplasia were less present in PCC; however, desmoplasticstroma was more prominent in PCC. Similarly, linitis and perineural invasion were more frequent in PCC. A higher proportion of patients with PCC presented with T4 stage (PCC: 55.7%; NPCC: 34.4%; p = 0.033) and N3 (PCC: 65.6%; NPCC: 29.5%; p \< 0.001). PCC was more likely to present at an advanced AJCC stage (stages 3 and 4). Peritoneal carcinomatosis was more frequent in PCC group (p = 0.004); however, hepatic metastases were more frequent in NPCC group (p = 0.031). Finally, the rate of complete resection was lower in PCC group. There was no significant difference in recurrence rate between the two groups.

3.2. Overall survival analysis {#sec3.2}
------------------------------

The 1-year, 3-year and 5-year survival rates of PCC patients were 70.7%, 31.8% and 22.6%, respectively. The 1-year, 3-year and 5-year survival rates of NPCC patients were 68.3%, 55.8% and 43.2%,respectively. There was no significant difference in the overall survival rate between patients with PCC and those with NPCC (p = 0.241) ([Figure 1](#fig1){ref-type="fig"}).Figure 1Survival curves in patients with PCC and NPCC.Figure 1

3.3. Univariate analysis {#sec3.3}
------------------------

In PCC group, the 5-year survival rate was influenced by age, malnutrition, tumor size, tumor location, involvement of adjacent organs, extent of gastrectomy, postoperative chemotherapy, TN stage, distant metastasis, peritoneal dissemination, lymphatic invasion, and complete resection (R0) ([Table 2](#tbl2){ref-type="table"}). Age \>60 years ([Figure 2](#fig2){ref-type="fig"}), malnutrition, involvement of adjacent organs, extent of gastrectomy, postoperative chemotherapy and lymphovascular invasion were specific prognostic factors for PCC. Linitis, postoperative complication and perineural invasion were prognostic factors associated with survival in NPCC group.Table 2Univariate analysis of factors influencing the overall survival in PCC and NPCC groups.Table 2VariableAll patientsPCC groupNPCC groupNumber (%)5 year survival (%)PNumber (%)5 year survival (%)PNumber (%)5 year survival (%)pGender0.6230.2720.478Male54 (61.4)37.523 (53.5)36.631 (68.8)38.4Female34 (38.625.320 (46.5)10.614 (31.2)52.4Age (years)0.248**0.003**0.978≤6048 (54.5)32.431 (72.1)27.717 (37.7)42.8\>6040 (45.5)31.812 (27.9)8.328 (62.3)43.5Malnutrition**0.0170.021**0.268No20 (22.7)56.411 (25.6)50.69 (20)62.5Yes66 (75)24.232 (74.4)16.134 (75.5)35.2Missing data2 (2.3)2 (4.5)Tumor size (cm)**0.044**0.2780.125≤536 (40.9)42.317 (39.5)37.819 (42.2)46.8\>552 (59.1)25.529 (60.5)926 (57.8)41.5Linitis**0.051**0.227**0.002**No79 (89.8)36.735 (81.4)3044 (97.7)44.2Yes9 (10.2)08 (18.6)01 (2.3)0Tumor location**0.004\<0.0010.008**Body42 (47.7)48.620 (46.5)53.722 (48.9)45.1Antrum43 (48.9)18.521 (48.8)022 (48.9)44.3Whole stomach3 (3.4)02 (4.701 (2.2)0Invasion of adjacent organs**0.092\<0.001**0.629No73 (82.9)34.538 (88.4)2535 (77.7)45.9Yes15 (17.1)∗5 (11.6)010 (22.3)∗Gastrectomy0.059**0.003**0.587Total60 (68.2)37.331 (72)35.629 (64.4)42.8Subtotal28 (31.8)23.712 (28)016 (35.6)44.6Number of lymph nodes retrieved0.0740.0930.340≤1624 (27.3)2211 (25.6)12.113 (28.9)28.8\<16--25≤28 (31.8)43.615 (34.8)47.313 (28.9)43.1\>2536 (40.9)31.117 (39.614.619 (42.2)69.7Postoperative complication**0.016**0.401**0.007**No71 (80.7)34.134 (79)22.437 (82.2)45.7Yes17 (19.3)26.59 (21)27.88 (17.8)25Postoperative chemotherapy0.347**0.036**0.483No39.840.836.9Yes271348.5Lymphovascular invasion**0.0050.004**0.141No20 (22.7)61.610 (23.2)65.610 (22.2)55.6Yes68 (77.3)24.733 (76.8)035 (77.8)40.2Perineural invasion**0.001**0.062**0.016**No25 (28.4)66.36 (13.9)6019 (42.2)71Yes63 (71.6)20.237 (86.1)1626 (57.8)24.4Stroma**0.050**0.458**0.045**Inflammatory microenvironment57 (68.7)37.223 (54.7)30.634 (82.9)41.9Desmoplasia26 (31.3)∗19 (45.3)∗7 (17.1)0Resection**\<0.001\<0.001\<0.001**complete (R0)73 (82.9)3933 (76.7)28.340 (88.8)49.6incomplete (R1-R2)15 (77.1)010 (23.3)05 (11.2)0Peritoneal carcinomatosis**\<0.0010.0080.021**No75 (85.3)38.532 (74.5)29.843 (95.6)45.7Yes13 (14.7)011 (25.5)02 (4.4)0pT stage**\<0.0010.023\<0.001**T110 (11.4)85.72 (4.6)1008 (17.8)80T27 (7.9)68.64 (9.3)753 (6.6)66.7T333 (37.5)31.716 (37.3)017 (37.8)66.8T438 (43.2)∗21 (48.8)∗17 (37.8)∗pN stage**\<0.001\<0.0010.001**N028 (31.8)75.413 (30.3)53.715 (33.3)93.3N113 (14.8)34.12 (4.7)5011 (24.5)24.6N211 (12.5)03 (6.8)∗8 (17.7)0N336 (40.9)5.325 (58.2)∗11 (24.5)12.1pM stage**\<0.0010.002\<0.001**M070 (79.5)41.531 (72.1)30.939 (86.6)50.8M118 (20.5)012 (27.9)06 (13.4)0pTNM stage**\<0.001\<0.001\<0.001**Stage I13 (14.7)67.15 (11.6)808 (17.7)87.5Stage II24 (27.3)52.110 (23.2)30.914 (31.1)67.5Stage III33 (37.5)11.316 (37.3)∗17 (37.8)19.4Stage IV18 (20.5)012 (27.9)06 (13.4)0HistologyPCC43 (48.8)22.60.241NPCC45 (51.2)43.2NPCCC well differentiated20 (22.7)48.80.254[^3][^4][^5]Figure 2Survival curves in patients aged above 60 years with PCC and NPCC.Figure 2

3.4. Multivariate analysis of Cox proportional hazards regression model {#sec3.4}
-----------------------------------------------------------------------

Multivariate Cox proportional hazards models included variables associated with survival in PCC and NPCC group. Age \> 60 years, invasion of adjacent organs, incomplete resection, and depth of invasion were specific significant independent prognostic factors in PCC group. However postoperative complication was a significant prognostic indicator only in NPCC group. Over all patients presenting gastric ADK, the Cox proportional hazards model showed that age \> 60, invasion of adjacent organs, incomplete resection, depth of invasion, lymph node metastasis and distant metastasis were significant prognostic factors. PCC histology type was not a prognostic factor on multivariate analysis in our cohort ([Table 3](#tbl3){ref-type="table"}).Table 3Multivariate analysis of overall survival.Table 3VariableAll casesPCC groupNPCC groupHRIC95%PHRIC95%PHRIC95%PAge \> 602.901.25--6.730.0136.441.71-24.190.006Invasion of adjacent organs3.021.18--7.700.02140.314.15--390.780.001Incomplete resection5.722.16--15.08\<0.00128.025.19--151.17\<0.001pT2.521.34--4.760.0043.741.35-10.310.011pN3.271.74--6.13\<0.0011.721.07-2.770.025pM3.031.14--8.070.0265.991.65-21.760.0063.301--10.910.049Postoperative complication4.841.46--160.010

4. Discussion {#sec4}
=============

4.1. Pronostic value of PCC {#sec4.1}
---------------------------

Based on the analysis of a cohort of 122 patients with gastric ADK, we didn\'t find a pejorative prognostic value of PCC histological subtype on overall survival. PCC has not been identified as poor prognostic factor neither in univariate nor in multivariate analysis. Interestingly, we found that advanced age, adjacent structures invasion and positive resection margins are specific prognostic factors in PCC. To the best of our knowledge, this was the first Tunisian study that focused on prognostic significance of gastric PCC.

Despite the improvement of the diagnostic means and the therapeutic management of gastric carcinoma, its prognosis remains poor and five-year survival rate, all stages combined, is of 25% \[[@bib13]\]. This may be explained by the steady increase in the incidence of PCC which accounts for up to 50% of gastric carcinomas \[[@bib9]\] and whose prognosis is supposed to be poor. However, few studies support this hypothesis, like ours. Published data about the prognostic value of different histological subtypes of gastric carcinomas appears contradictory and seems to be influenced by the classification used (Lauren classification \[[@bib14]\], WHO classification \[[@bib12]\] or other classifications) and tumor stage (early or advanced).While the pejorative nature of the diffuse gastric carcinoma of the Lauren classification \[[@bib3], [@bib14]\] is confirmed, the prognostic value of PCC in the WHO classification remains controversial \[[@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib15], [@bib16], [@bib17]\]. In fact, in accordance with our results, a study carried out by Taghavi et al. in 2012 on 10246 patients with gastric ADK enrolled from 17 cancer registries found no association between PCC histological subtype and survival rate \[[@bib6]\]. This result was confirmed by Shim et al. in 2014 on a cohort of 2643 patients \[[@bib16]\]. Indeed, in Asian studies that included only gastric ADK \[[@bib4], [@bib5], [@bib7], [@bib17], [@bib18], [@bib19]\], it is reported that the survival rate of patients in PCC group is better than that of NPCC group \[[@bib5], [@bib20], [@bib21]\]. PCC histological subtype has even been recently identified as an independent factor of good prognosis \[[@bib5], [@bib23]\]. This was explained by the fact that the majority of superficial PCC is stage T1a and associated with weak lymph node metastases. Recent studies found that PCC is often discovered at early stage because it gives more ulcerated forms on endoscopy which is easily recognizable \[[@bib5], [@bib16], [@bib17], [@bib22]\]. In our study, the 5-year survival of the early PCC group was better than in NPCC group, but the difference was not significant (100% vs. 80%; p = 0.52). However, for patients with advanced gasrtic carcinoma, the prognostic value of histological subtype remains controversial \[[@bib4], [@bib5], [@bib6], [@bib7], [@bib15], [@bib19], [@bib23]\]. Many studies have shown that advanced stage PCC gives more parietal invasion (in our study: pT4: PCC = 55,7% vs NPCC = 34.4%; p = 0.033), more lymph node metastases \[53,143,145,148\], more incomplete surgical resection \[[@bib8], [@bib17], [@bib21], [@bib24], [@bib27]\] (in our study, R1/R2: PCC = 31.1% vs NPCC = 9.8%; p = 0.004). However, almost all them, failed to identify PCC subtype as an independent poor prognostic factor.

4.2. Survival analysis {#sec4.2}
----------------------

Some studies found that 5-year survival rate appears to be better in patients with PCC \[[@bib6], [@bib15]\]. They explain these results by the fact that patients with PCC are often younger with less comorbidity and less postoperative complications compared to the NPCC group. In our study, the PCC group was, on average, 10 years younger than the NPCC group (p = 0.001). Similarly, postoperative complications was an independent factor of poor prognosis only for NPCC group (HR = 4.8, 95% CI: 1.46--16.08, p = 0.010). The 5-year survival rate of the advanced PCC group was lower compared to the group of NPCC but with no significant difference (16% vs 35%, p = 0.538).Interestingly, we found some differences in prognostic factors between the two groups. Indeed, age\> 60 years, invasion of adjacent organ, incomplete resection, the pT and pM stages were independent prognostic factors significantly decreasing survival in PCC group. Postoperative complications, pN and pM stages were independent prognostic factors significantly decreasing the survival in the NPCC group. In our cohort, there was no significant difference between PCC group and NPCC group regarding recurrence (27.7% vs. 23.1%). PCC recurred as peritoneal carcinomatosis in 77.7% and as distant metastases in NPCC in 66.6% with no significant difference. It is actually advised to perform a first exploratory laparoscopy to search cancer cells in the peritoneum in PCC. Prophylactic Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) is currently widely used in PCC since peritoneal carcinomatosis worsen prognosis \[[@bib25], [@bib26]\]. Furthermore, PCC seems to be less chemosensitive than NPCC and recent studies suggest that it would have a specific sensitivity profile to taxanes and anti-angiogenic agents \[[@bib9], [@bib27], [@bib28], [@bib29]\]. In our study, we have interestingly found that survival rate of chemotherapy group was significantly lower than the one with no chemotherapy suggesting that chemotherapy may worsen the prognosis of PCC. Thus it should be managed differently. In addition, although peri-operative chemotherapy is recommended in all gastric carcinomas from stage IA, its interest in PCC remains to be proven. In our study, no patient received peri-operative chemotherapy because it was not available. In fact, chemotherapy is frequently retarded because only one oncology centre is available in our country. Patients are therefore surgically managed.

In conclusion, because of its carcinogenesis, epidemiology, clinical aspects, pathological, molecular and genetic features, gastric PCC should be considered as a distinct pathology among gastric carcinomas. This type of tumor presented specific prognostic factors in our study. Nevertheless, large multicentric studies will help to improve our knowledge about this deadly cancer and its management.
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[^1]: PCC, poorly cohesive carcinoma; NPCC, non poorly cohesive carcinoma.

[^2]: P value significant if lower than 0.05.

[^3]: PCC, poorly cohesive carcinoma; NPCC, non poorly cohesive carcinoma.

[^4]: ∗Censored case number does not allow an accurate estimation of survival.

[^5]: P value significant if lower than 0.05.
